Top Story

NSCLC treatment market estimated to exceed $7.9 billion by 2020

September 14, 2014

The global market value of non-small cell lung cancer treatment will increase from $5.1 billion in 2013 to more than $7.9 billion by 2020 with a compound annual growth rate of 6.6%, according to a report from GBI Research.

The company says that this growth will be primarily driven by the introduction of several premium therapies which either replace or combine with generic chemotherapies, particularly in second-line and squamous cell treatment settings.

FDA News

FDA lifts clinical hold on vantictumab for NSCLC, breast cancer, pancreatic cancer

August 31, 2014
OncoMed Pharmaceuticals recently announced that the FDA has removed the partial clinical hold on enrollment in phase 1 clinical trials for the company’s monoclonal…
In the Journals

Post-hospitalization intervention strategy yielded higher smoking cessation rates

August 26, 2014
Adult smokers recently released from the hospital achieved higher 6-month smoking cessation rates when they followed a post-discharge strategy compared with standard…
Institution Notes

NIH launches cohesive precision medicine trials for lung cancer

August 24, 2014
The NIH recently announced the launch of three integrated precision medicine trials to pinpoint early-stage lung cancer patients with tumors that harbor rare genetic…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »

Filter By:

Industry News

NSCLC treatment market estimated to exceed $7.9 billion by 2020

September 14, 2014
The global market value of non-small cell lung cancer treatment will increase from $5.1 billion in 2013 to more than $7.9 billion by 2020 with a…
FDA News

FDA lifts clinical hold on vantictumab for NSCLC, breast cancer, pancreatic cancer

August 31, 2014
OncoMed Pharmaceuticals recently announced that the FDA has removed the partial clinical hold on enrollment in phase 1 clinical trials for the…
In the Journals

Post-hospitalization intervention strategy yielded higher smoking cessation rates

August 26, 2014
Adult smokers recently released from the hospital achieved higher 6-month smoking cessation rates when they followed a post-discharge strategy…
Institution Notes

NIH launches cohesive precision medicine trials for lung cancer

August 24, 2014
The NIH recently announced the launch of three integrated precision medicine trials to pinpoint early-stage lung cancer patients with tumors that…
In the Journals

Prior emphysema, chronic bronchitis linked to increased risk for lung cancer

August 22, 2014
Individuals who were previously diagnosed with chronic bronchitis or emphysema appear to be at increased risk for developing lung cancer, according…
figure Institution Notes

Cancer associations urge FDA to extend tobacco regulation

August 16, 2014
The American Society of Clinical Oncology and the American Association for Cancer Research recently issued a
figure In the Journals

Long-term aspirin use reduced risk for cancer, cardiovascular events

August 14, 2014
Average-risk adults must adhere to a daily prophylactic aspirin regimen for 5 years to derive its protective benefits against cancer, myocardial…
figure In the Journals

Lung cancer rates in decline, but varied by demographic

August 11, 2014
Overall lung cancer rates are declining in the United States, but the patterns of prevalence differ based on sex, histologic type, racial/ethnic…
Industry News

Halaven fails to meet primary endpoint in NSCLC

August 8, 2014
Results from a phase 3 trial have found that eribulin did not meet its primary endpoint of OS for the treatment of non-small cell lung cancer that…
In the Journals Perspective

Smoking habits persisted among cancer survivors

August 6, 2014
Nearly one-tenth of cancer survivors continued to smoke 9 years after diagnosis, according to results of a population-based study.Among that group…
More Headlines »